Multiple Functional Variants at 13q14 Risk Locus for Osteoporosis Regulate RANKL Expression Through Long-Range Super-Enhancer
- 12 March 2018
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 33 (7) , 1335-1346
Abstract
RANKL is a key regulator involved in bone metabolism, and a drug target for osteoporosis. The clinical diagnosis and assessment of osteoporosis are mainly based on bone mineral density (BMD). Previous powerful genome-wide association studies (GWASs) have identified multiple intergenic single nucleotide polymorphisms (SNPs) located over 100 kb upstream of RANKL and 65 kb downstream of AKAP11 at 13q14.11 for osteoporosis. Whether these SNPs exert their roles on osteoporosis through RANKL is unknown. In this study, we conducted integrative analyses combining expression quantitative trait locus (eQTL), genomic chromatin interaction (Hi-C), epigenetic annotation and a series of functional assays. The eQTL analysis identified six potential functional SNPs (rs9533090, rs9594738, r8001611, rs9533094, rs9533095 and rs9594759) exclusively correlated with RANKL gene expression (P < 0.001) at 13q14.11. Co-localization analyses suggested that eQTL signal for RANKL and BMD-GWAS signal shared the same causal variants. Hi-C analysis and functional annotation further validated that the first 5 osteoporosis SNPs are located in a super-enhancer region to regulate the expression of RANKL via long-range chromosomal interaction. Particularly, dual-luciferase assay demonstrated that the region harboring rs9533090 in the super-enhancer has the strongest enhancer activity, and rs9533090 is an allele-specific regulatory SNP. Furthermore, deletion of the region harboring rs9533090 using CRISPR/Cas9 genome editing significantly reduced RANKL expression in both mRNA level and protein level. Finally, we found that the rs9533090-C robustly recruits transcription factor NFIC, which efficiently elevates the enhancer activity and increases the RANKL expression. In summary, we provided a feasible method to identify regulatory noncoding SNPs to distally regulate their target gene underlying the pathogenesis of osteoporosis by using bioinformatics data analyses and experimental validation. Our findings would be a potential and promising therapeutic target for precision medicine in osteoporosis. This article is protected by copyright. All rights reservedKeywords
Funding Information
- National Natural Science Foundation of China (81573241, 31771399, 31471188, 31701095)
- China Postdoctoral Science Foundation (2016M602797)
This publication has 64 references indexed in Scilit:
- The long-range interaction landscape of gene promotersNature, 2012
- Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fractureNature Genetics, 2012
- Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traitsNature Genetics, 2012
- The mouse RANKL gene locus is defined by a broad pattern of histone H4 acetylation and regulated through distinct distal enhancersJournal of Cellular Biochemistry, 2011
- Functional and Mechanistic Diversity of Distal Transcription EnhancersCell, 2011
- GCTA: A Tool for Genome-wide Complex Trait AnalysisThe American Journal of Human Genetics, 2011
- Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studiesNature Genetics, 2009
- Nuclear Factor I transcription factors regulate IGF binding protein 5 gene transcription in human osteoblastsBiochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, 2009
- Regulation of a remote Shh forebrain enhancer by the Six3 homeoproteinNature Genetics, 2008
- Multiple enhancer regions located at significant distances upstream of the transcriptional start site mediate RANKL gene expression in response to 1,25-dihydroxyvitamin D3The Journal of Steroid Biochemistry and Molecular Biology, 2007